Programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies
Programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies interact with a protein called PD-1 on T-cells and can be useful in determining if certain immunomodulation therapies can be used in treatment of certain types of cancers. PD-L1 is a major immune checkpoint protein that mediates antitumor immune suppression and response.
Imaging applications
Nuclear medicine
PET
Some studies show that agents, such as the peptide-based imaging agent, gallium-68-WL12 can be used to detect PD-L1 expression in tumors non-invasively by positron emission tomography (PET) .
See also
